Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I

Posted: December 17, 2020 at 7:55 am

Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021 Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021

Originally posted here:
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I

Related Posts